Thymogen (Oglufanide): Evidence, Mechanism & Status

Thymogen is a synthetic dipeptide — L-α-glutamyl-L-tryptophan (Glu-Trp) — first developed in the late-Soviet bioregulator program of Vladimir Khavinson and registered as an immunomodulatory drug in the USSR/Russia in 1990.5 The same molecule was developed independently in the West as the antiangiogenic agent oglufanide / IM-862, and it is the unusual "bioregulator" peptide that actually reached large, rigorous human trials.3 This monograph separates what is proven from what is hyped.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Thymogen is not an FDA-approved drug; it is sold as a "research chemical not for human use." Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Thymogen and how does it work?

Thymogen is the salt of L-α-glutamyl-L-tryptophan, a two-amino-acid peptide of glutamic acid and tryptophan (sequence Glu-Trp), with molecular formula C₁₆H₁₉N₃O₅ and molecular weight near 333 g/mol; the free peptide carries CAS 38101-59-6 and the disodium salt CAS 122933-59-9.1415 It was isolated by reversed-phase HPLC from the calf-thymus extract Thymalin and then synthesized as a standalone drug.5 A revealing stereochemical point: the mirror-image D-enantiomer (D-Glu-D-Trp), marketed as Thymodepressin, has the opposite effect — immunosuppression — underscoring that the activity is sequence- and chirality-specific, not a generic amino-acid effect.5

There are two mechanistic stories with very different evidence levels. The immunomodulatory account is preclinical: in the Khavinson bioregulator framework, ultra-short peptides are proposed to enter cells and modulate gene transcription tissue-specifically rather than act through a surface receptor, with reported effects including stimulation of T-lymphocyte precursors, normalization of the CD4/CD8 ratio, raised intracellular cyclic AMP in T-cells, and activation of monocyte and granulocyte phagocytosis.5 In a human THP-1 monocyte cell line, Thymogen and sibling peptides modulated proliferative signaling, including tyrosine phosphorylation of mitogen-activated kinases.6 The chromatin/gene-binding model remains unproven by independent Western replication (Grade C).6 The antiangiogenic account is the better-characterized human effect: as oglufanide / IM-862 the molecule lowers vascular endothelial growth factor (VEGF), and this VEGF-lowering effect was confirmed pharmacodynamically in humans — the one mechanistic claim with direct human support (Grade B).3

What is the evidence by indication?

Thymogen's human evidence is concentrated in oncology, where the trials were rigorous and the results were mostly null or negative. The table summarizes the picture; reviewers and registries are the source for non-oncology claims.5

The Kaposi sarcoma data are the highest quality and decisive. A Phase II study (n=44; intranasal 5 mg) reported good tolerability and apparent antitumor activity.2 The definitive 24-week Phase III then randomized 202 HIV-positive patients (104 IM-862 vs 98 placebo, 5 mg intranasally every other day): response rates were 23% versus 21% (P = 0.46 — no difference), and IM-862 was associated with a shorter median time to progression (16 vs 35 weeks, P = 0.012). The authors concluded it was "not superior to placebo and may accelerate time to progression," attributing the earlier optimism to concurrent HAART-driven immune reconstitution.1 In metastatic renal cell carcinoma, a Phase II trial (n=25; intranasal 20 mg three times daily) produced zero objective responses, with 8 of 25 patients achieving stable disease — yet it confirmed the mechanism, with plasma VEGF falling from a baseline median near 280 pg/mL to about 200 pg/mL at week 4 (P = 0.02) and about 120 pg/mL at week 8 (P = 0.0065).3 Readers can confirm the Phase III primary record at PubMed (PMID 15598977).

The marketed respiratory and immune-support indications are the most promoted and the most weakly evidenced in Western terms. The Russian registered-drug dossier describes benefit in upper-respiratory infections, post-chemotherapy immunosuppression, and various infections, but these are not PubMed-indexed double-blind RCTs and have no independent Western replication.516 Animal data (survival benefit in mouse sepsis and candidiasis) are biologically suggestive but remain Grade C.5 Chronic hepatitis C was described as a development-stage indication for intranasal oglufanide but has been overtaken by direct-acting antivirals, with no completed positive RCT located.8 A single rat study reported slowed aging and reduced spontaneous tumor incidence — animal-only, and not to be extrapolated to humans given the oncology harm signal.7

What doses appear in the literature, and how safe is it?

Reported strictly as information, not a protocol. The oncology trials used the intranasal route: 5 mg every other day in Kaposi sarcoma, up to 20 mg three times daily in renal cell carcinoma.23 Russian registered forms include an intramuscular injection solution, a metered nasal spray, and a 0.05% topical cream.5 Oral delivery is the weak link: the unmodified dipeptide is hydrophilic and peptidase-labile, with negligible oral bioavailability, and preclinical work had to attach lipid and glycosyl groups to achieve permeability and enzymatic stability — direct evidence that any oral "capsule" product faces a real absorption problem for the intact peptide.417 A robust human plasma half-life is not well published; the every-other-day intranasal schedule implies a functional effect outlasting the short expected residence of a free dipeptide.2

On safety, tolerability in the controlled trials was good: in renal cell carcinoma there was no grade 3-4 drug-related toxicity, only grade 1-2 sinusitis and grade 1 headache from the nasal route, plus one possible ulcerative-colitis flare.3 The Kaposi sarcoma trials similarly described it as well tolerated.2 The key nuance is not a classic side effect but the Phase III signal of shorter time to tumor progression than placebo — the opposite of the marketed "safe immune-booster" framing.1 Because the molecule both lowers VEGF and activates immunity, two opposite theoretical concerns coexist: immune activation could be undesirable in autoimmune disease, and angiogenic modulation in malignancy is unpredictable.3 Pregnancy and lactation have no human data and should be considered contraindicated by default; drug interactions are not formally studied; and there is no Western-standard post-marketing safety dataset.16

What is the FDA and WADA status in 2026?

In the United States, Thymogen is not FDA-approved in any form, is not a component of any approved drug, and is not listed on the FDA 503A or 503B compounding bulk-substance lists — so it cannot be lawfully compounded for patient use under those pathways.910 During the FDA's 2023-2026 peptide-compounding actions, Thymogen / Glu-Trp was not among substances cleared for compounding; it sits outside the legitimate compounding framework entirely and is marketed in the U.S. only as a research chemical not for human use.11 No EMA marketing authorization was located in the European Union. In the Russian Federation it has been registered as a drug since 1990 (injectable, nasal spray, topical cream) — the basis of all clinical-use claims, but not equivalent to Western approval.5

For athletes the conservative reading is clear. Thymogen is not explicitly named on the current WADA Prohibited List, but because it is a non-approved-for-human-use substance with pharmacological activity, it is plausibly captured by Class S0 (Non-Approved Substances), which prohibits any substance not approved by a government health authority for human therapeutic use.1213 Under strict liability, athletes should treat it as prohibited at all times and confirm via Global DRO.

Bottom line. Thymogen / oglufanide / IM-862 is the unusual bioregulator peptide that actually got tested properly, and the rigorous human verdict is sobering. It is a genuine VEGF-lowering antiangiogenic agent in humans (Grade B) and is very well tolerated at trial doses, but as monotherapy it does not produce tumor responses, and in a 202-patient double-blind Phase III it was no better than placebo and possibly worse (Grade A negative).1 The consumer-facing immune-support, respiratory and anti-aging positioning rests on Russian single-program registration and animal data (Grade C-D).5 Human pharmacokinetics are poorly defined, oral bioavailability of the intact peptide is likely negligible,4 and it remains FDA-unapproved and outside the legitimate U.S. compounding framework in 2026. Regulatory facts here are current as of June 2026 and should be re-verified before relying on them.